

# NIH funding opportunities

26 Feb 2024 (#08)



**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**



See all Important Notices, Parent Announcements and Notice of Special Interest below

**Plan your application. Before starting your application attend**

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

**To prepare an application can take *4-18 months*.**

**From submission to receiving a Notice of Award can take *10 months***

## Important Notices

Register for webinar series on how to plan for & write an NIH grant application. [NIAID Grant Writing Webinar Series](#)

- Dates: February 22–July 18, 2024

## Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

[NOT-CA-24-032](#) Administrative supplements to understand effects of within-group heterogeneity on cancer control outcomes in underrepresented populations. The goal of this NOSI from the National Cancer Institute (NCI) is to support administrative supplements for currently funded investigators to better understand within-group factors that contribute to cancer prevention and control outcomes and intervention effectiveness in populations that are

underrepresented in or excluded from cancer research. This administrative supplement would provide funding for one year to initiate or enhance evaluation of heterogeneity within populations and/or how this heterogeneity influences cancer outcomes, within the scope of the parent grant. Submissions must be received by March 29, 2024, April 29, 2024, at 5:00 PM local time of applicant organization.

**[NOT-CA-24-033 Telehealth Research in Cancer Care.](#)** The purpose of this NOSI is to highlight the interest of [NCI's Division of Cancer Control and Population Sciences](#) in receiving investigator-initiated applications for proposing research on the use and impact of telehealth in cancer-related care, and the implications of telehealth policy changes on cancer care access, outcomes, and health equity. This Notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through March 16, 2026.

**[NOT-OD-24-058 Developing and Testing Multi-level Physical Activity Interventions to Improve Health and Well-Being](#)** The Office of Disease Prevention and participating Institutes, Centers and Offices (ICOs) are issuing this Notice to highlight our interest in highly innovative multi-level interventions to increase and maintain health-enhancing physical activity in a wide range of population groups, including populations that experience health disparities, children, older adults, and persons at risk for mental/behavioral health conditions, and any subpopulations that can be characterized by the intersection of two or more of these descriptors. Relevant physical activity intervention research includes translational research for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, as well as studies seeking to adopt existing evidence-based interventions in a new context (e.g., population, setting, etc.). Research studies should be based on well-established theory, existing data, and/or evidence-based interventions. Furthermore, studies may focus on establishing efficacy, effectiveness, or dissemination and implementation of multi-level interventions. This NOSI applies to due dates on or after 5 June 2024 and subsequent receipt dates through 14 November 2027.

## Notice of Funding Opportunity (NOFO)

1. **[PAR-24-151 Translational Neural Devices \(R61/R33 - Clinical Trial Optional\).](#)** The purpose of this NOFO is to encourage investigators to pursue translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study (R61 phase), as well as a subsequent small clinical study (R33 phase). The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO utilizes an Exploratory/Developmental Phased Award and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Transition from the R61 to the R33 phase is contingent upon the successful completion of proposed milestones. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

**Due dates:** May 29, 2024 through to January 28, 2027. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** The proposed project period for the R61 phase must not exceed 2 years. The proposed project period for the R33 phase must not exceed 4 years. The total duration of the R61 and R33 may not exceed 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

2. **[RFA-DA-25-043 Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction \(R01 - Clinical Trials Optional\).](#)** This notice of funding opportunity (NOFO) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. This NOFO requires a plan for enhancing diverse perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation

**Due dates:** July 17, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** Application budgets will be limited to \$350,000 in direct costs/year. The proposed budget needs to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

**3. [RFA-MH-25-100](#) BRAIN Initiative: Scaled reagent resources for brain cell type-specific access across vertebrate species (U01 Clinical Trial Not Allowed).** This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the scaling up of brain cell type-specific molecular or genetic access reagents to study circuit function. Scaled engineering and validation of cell type-specific reagents are priorities to be supported. Applications are sought for Reagent Resource for Design and Development projects that scale up the creation of these tools for several vertebrate species, including in experimental animals and human ex vivo tissues or cells. Projects will integrate: scaled engineering, validation, cataloguing, and adaptation into easily disseminable formats of reagents. Scaled up projects are sought that will develop tens to hundreds of cell type-selective reagents. Validated reagents produced in these projects are intended to be distributed to neuroscience researchers via centralized Production and Distribution Facilities to be supported separately. This NOFO is part of the BRAIN Initiative Armamentarium project, whose overall goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple vertebrate species. This NOFO will foster close interaction between technologists, disseminators, and neurobiologists in a research consortium including investigators funded by other Armamentarium NOFOs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

**Due dates:** June 14, 2024, January 17, 2025. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** Issuing IC and partner [components](#) intend to commit an estimated total of \$14,000,000 per year to fund 4 to 6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

<b>Faculty of Medicine and Health Sciences Research &amp; Internationalisation Development &amp; Support (RIDS) &amp; Grants Management Office (GMO)</b> 009 K <sup>th</sup> Floor, Teaching Block, Tygerberg Campus.	<b>Stellenbosch Campus Division for Research Development (DRD)</b> 2041 Krotoa Building, Ryneveld Street
<b>Enquiries:</b> <a href="mailto:cdevries@sun.ac.za">cdevries@sun.ac.za</a> / <a href="mailto:fmhsgmo@sun.ac.za">fmhsgmo@sun.ac.za</a>	<b>Enquiries:</b> <a href="mailto:research@sun.ac.za">research@sun.ac.za</a>
<b>Add "Interest in NIH opportunity" in the subject line. Add the notice number in the text of the email.</b>	